EXTON, Pa., Oct. 4, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the results from an analysis of a patient-database involving Cinryze ® (C1 esterase inhibitor [human]) demonstrating that ViroPharma's Path to Independence™ program, a self-administration training and support program for hereditary angioedema (HAE) patients receiving prophylactic Cinryze, positively impacts the site of care in favor of home/self-administration as well as adherence to routine preventive therapy. These findings were presented at the Academy of Managed Care Pharmacy (AMCP) Educational Conference in Cincinnati.
A similar analysis of this patient-database of 516 patients to assess the site of care was first conducted in June 2010. Six months later, ViroPharma's Path to Independence training and support program was implemented to educate eligible patients on self-administration of Cinryze. In early 2012, patient-reported demographic data from this Cinryze database of 789 HAE patients were examined. These results were compared to the 2010 analysis and reflect distributions of site of care for similar lengths of time before and after the initiation of the training and support program.
The site of care for patients receiving Cinryze (N=789) was 75.8 percent at home, 16.1 percent at an infusion center, and 8.1 percent at a physician's office, compared to 47.1, 23.3, and 27.5 percent, respectively, from the 2010 analysis. Of the 75.8 percent patients who infused at home, 57.9 percent self-administered, 26.6 percent were infused by a home health agency nurse, 14.7 percent by a family member, and 0.8 percent by other. Overall, self-administration was reported in 43.7 percent of patients compared to 20.0 percent from the 2010 analysis. Patients required an average of 5 visits to be successfully trained. Discontinuation rates of trained patients were 5 percent compared to 10 percent for untrained patients suggesting that non-program patients were twice as likely to stop therapy.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts